Revenue
$7.12M
Gross Margin
+99.5%
Operating Margin
-670.2%
Net Margin
-339.3%
Income statement waterfall for Ovid Therapeutics (OVID) — TTM through Q1 2026
Net income: -$24.2M
Margin breakdown for Ovid Therapeutics (OVID) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $7.12M | $7.12M |
| Cost of Revenue | -$35K | $7.09M |
| Gross Profit | $7.09M | $7.09M |
| Operating Expenses | -$54.8M | -$47.7M |
| Operating Income | -$47.7M | -$47.7M |
| Other Income / Expense | $23.6M | -$24.2M |
| Pre-tax Income | -$24.2M | -$24.2M |
| Income Tax | $0.00 | -$24.2M |
| Net Loss | -$24.2M | -$24.2M |
- Revenue$7.12M
- Cost of Revenue-$35K
- Gross Profit$7.09M
- Operating Expenses-$54.8M
- Operating Income-$47.7M
- Other Income / Expense$23.6M
- Pre-tax Income-$24.2M
- Income Tax$0.00
- Net Loss-$24.2M
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.